Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever
Pediatrics International · 2023
DOI: 10.1111/ped.15588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, 2023. Verfasst von Hatice Kubra Erkilet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Familial Mediterranean Fever, Amyloidosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The aim of this study was to evaluate the efficacy and safety of anti‐interleukin‐1 (IL‐1) therapies in colchicine‐resistant pediatric patients with familial Mediterranean fever (FMF).
Methods
In this study, we retrospectively evaluated 656 children with FMF and 27 patients who had been treated with anti‐IL‐1 therapies (anakinra/canakinumab) . Clinical and laboratory features, MEFV gene mutations, treatment responses were investigated.
Results
Twenty of the patients were treated with anakinra (the treatment of 6 patients who initially used anakinra was switched to canakinumab in the follow‐up period), and 13 patients were treated with canakinumab. Clinical symptom and severity scores decreased in all patients A decrease in acute phase reactants was also observed in patients. A total of 18 (66%) patients had a M694V homozygous mutation, while 24 (89%) patients had a M694V mutation, at least in one allele.
Conclusions
FMF patients with colchicine resistance may progress to amyloidosis. IL‐1 antagonist treatment could be used safely with a favorable outcome in pediatric patients with FMF resistance to colchicine therapy and/or who have renal amyloidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Faculty of Medicine, Gazi University, Ankara, Turkey.
- Department of Pediatric Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey.
ORCID-Profile: Hatice Kubra Erkilet, Deniz Gezgin Yildirim, Pelin Esmeray, Oğuz Söylemezoğlu
Zitieren
APA
Erkilet, H. K., Gezgin Yildirim, D., Esmeray, P., & Söylemezoğlu, O. (2023). Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever. Pediatrics International. https://doi.org/10.1111/ped.15588
Vancouver
Erkilet HK, Gezgin Yildirim D, Esmeray P, Söylemezoğlu O. Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever. Pediatrics International. 2023. doi:10.1111/ped.15588
BibTeX
@article{Erkilet2023,
author = {Erkilet, Hatice Kubra and Gezgin Yildirim, Deniz and Esmeray, Pelin and Söylemezoğlu, Oğuz},
title = {Efficacy and safety of anti‐interleukin‐1 in children with colchicine‐resistant familial Mediterranean fever},
journal = {Pediatrics International},
year = {2023},
doi = {10.1111/ped.15588}
}
EUVIMED